openPR Logo
Press release

Hypoparathyroidism Market Anticipated to Expand Rapidly During 2024-2034, Says DelveInsight | Bridgebio/Calcil ytix Therapeutics, Ascendis Pharma, EnteraBio, Shire

01-17-2025 03:26 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: ABNewswire

Hypoparathyroidism Market Anticipated to Expand Rapidly

The Key Hypoparathyroidism Companies in the market include - Ascendis Pharma, EnteraBio, Bridgebio/Calcil ytix Therapeutics, Shire, and others.

DelveInsight's "Hypoparathyroidism Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Hypoparathyroidism, historical and forecasted epidemiology as well as the Hypoparathyroidism market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Hypoparathyroidism market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hypoparathyroidism Market Forecast [https://www.delveinsight.com/sample-request/hypoparathyroidism-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Hypoparathyroidism Market Report:

*
The Hypoparathyroidism market size was valued approximately USD 360 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

*
In September 2024, Septerna, a clinical-stage biotechnology company leading the way in GPCR-targeted drug discovery, announced the initiation of dosing for the first participants in its Phase 1 clinical trial of SEP-786. This novel, potent, and selective oral small molecule parathyroid hormone 1 receptor (PTH1R) agonist is being developed to treat hypoparathyroidism. The Phase 1 trial, which includes both single-ascending dose (SAD) and multiple-ascending dose (MAD) cohorts, aims to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of SEP-786 in healthy adult volunteers.

*
In May 2024, Amolyt Pharma has reported that the FDA has awarded fast track designation to eneboparatide, a drug developed for the treatment of hypoparathyroidism. This medication, currently undergoing assessment in the Phase III Calypso clinical trial, has demonstrated promise in previous studies by enhancing critical calcium levels and bone health. Results from the Phase III trial are anticipated to be disclosed next year, with the specific date yet to be determined.

*
In May 2024, Ascendis Pharma A/S (Nasdaq: ASND) has disclosed findings from a post-hoc analysis of the Phase 3 PaTHway Trial, showcasing significant and enduring enhancements in renal function among adults with chronic hypoparathyroidism treated with TransCon PTH (palopegteriparatide).

*
The overall population with hypoparathyroidism in the 7MM was approximately 284,000 in 2022 and is anticipated to rise by the year 2034.

*
Around 22,500 individuals were affected by Hypoparathyroidism in Japan in 2022. Forecasts indicate an expected rise in these cases from 2024 to 2034.

*
In the EU4 and the UK, the United Kingdom had the highest prevalence of hypoparathyroidism in 2022, with approximately 35,000 cases, surpassing Germany and France. In contrast, Spain recorded the lowest prevalent population of hypoparathyroidism.

*
Upcoming therapies for hypoparathyroidism that show significant promise include TransCon PTH by Ascendis Pharma, EB612 (PTH 1-34), and Encaleret by Bridgebio/Calcilytix Therapeutics.

*
Key Hypoparathyroidism Companies: Ascendis Pharma, EnteraBio, Bridgebio/Calcil ytix Therapeutics, Shire, and others

*
Key Hypoparathyroidism Therapies: TransCon PTH, Encaleret, rhPTH(1-84), EB612 (EBP05), NPSP558, and others

*
The Hypoparathyroidism epidemiology based on gender analyzed that Hypoparathyroidism affects females more than males.

*
The Hypoparathyroidism market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hypoparathyroidism pipeline products will significantly revolutionize the Hypoparathyroidism market dynamics.

Hypoparathyroidism Overview

Hypoparathyroidism is a rare endocrine disorder characterized by insufficient levels of parathyroid hormone (PTH) in the body. PTH is produced by the parathyroid glands, which are located in the neck and are responsible for regulating calcium and phosphorus levels in the blood.

Get a Free sample for the Hypoparathyroidism Market Forecast, Size & Share Analysis Report: https://www.delveinsight.com/report-store/hypoparathyroidism-market [https://www.delveinsight.com/report-store/hypoparathyroidism-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Hypoparathyroidism Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Hypoparathyroidism Epidemiology Segmentation:

The Hypoparathyroidism market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Prevalence of Hypoparathyroidism

*
Prevalent Cases of Hypoparathyroidism by severity

*
Gender-specific Prevalence of Hypoparathyroidism

*
Diagnosed Cases of Episodic and Chronic Hypoparathyroidism

Download the report to understand which factors are driving Hypoparathyroidism epidemiology trends @ Hypoparathyroidism Epidemiology Forecast [https://www.delveinsight.com/sample-request/hypoparathyroidism-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Hypoparathyroidism Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hypoparathyroidism market or expected to get launched during the study period. The analysis covers Hypoparathyroidism market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Hypoparathyroidism Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Hypoparathyroidism Therapies and Key Companies

* TransCon PTH: Ascendis Pharma
*
Encaleret: Bridgebio/Calcil ytix Therapeutics

*
rhPTH(1-84): Shire

*
EB612 (EBP05): Entera Bio Ltd.

*
NPSP558: Shire

Discover more about therapies set to grab major Hypoparathyroidism market share @ Hypoparathyroidism Treatment Landscape [https://www.delveinsight.com/sample-request/hypoparathyroidism-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Hypoparathyroidism Market Strengths

*
Based on the route of administration, the parenteral method will remain the fastest-growing segment compared to oral methods.

*
Extensive cancer radiation treatment on the neck or face and new technology advancements for the treatment of hypoparathyroidism is set to further enhance the overall development of the hypoparathyroidism treatment market

Hypoparathyroidism Market Opportunities

*
In terms of drug class, calcium supplements might remain the most preferred in the coming future, with around 38% market share. PTH will also showcase a substantial growth rate.

*
Sales of hypoparathyroidism treatment drugs through retail pharmacies will generate maximum revenue, followed by hospital pharmacies.

Scope of the Hypoparathyroidism Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Hypoparathyroidism Companies: Ascendis Pharma, EnteraBio, Bridgebio/Calcil ytix Therapeutics, Shire, and others

*
Key Hypoparathyroidism Therapies: TransCon PTH, Encaleret, rhPTH(1-84), EB612 (EBP05), NPSP558, and others

*
Hypoparathyroidism Therapeutic Assessment: Hypoparathyroidism current marketed and Hypoparathyroidism emerging therapies

*
Hypoparathyroidism Market Dynamics: Hypoparathyroidism market drivers and Hypoparathyroidism market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Hypoparathyroidism Unmet Needs, KOL's views, Analyst's views, Hypoparathyroidism Market Access and Reimbursement

To know more about Hypoparathyroidism companies working in the treatment market, visit @ Hypoparathyroidism Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/hypoparathyroidism-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Hypoparathyroidism Market Report Introduction

2. Executive Summary for Hypoparathyroidism

3. SWOT analysis of Hypoparathyroidism

4. Hypoparathyroidism Patient Share (%) Overview at a Glance

5. Hypoparathyroidism Market Overview at a Glance

6. Hypoparathyroidism Disease Background and Overview

7. Hypoparathyroidism Epidemiology and Patient Population

8. Country-Specific Patient Population of Hypoparathyroidism

9. Hypoparathyroidism Current Treatment and Medical Practices

10. Hypoparathyroidism Unmet Needs

11. Hypoparathyroidism Emerging Therapies

12. Hypoparathyroidism Market Outlook

13. Country-Wise Hypoparathyroidism Market Analysis (2020-2034)

14. Hypoparathyroidism Market Access and Reimbursement of Therapies

15. Hypoparathyroidism Market Drivers

16. Hypoparathyroidism Market Barriers

17. Hypoparathyroidism Appendix

18. Hypoparathyroidism Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=hypoparathyroidism-market-anticipated-to-expand-rapidly-during-20242034-says-delveinsight-bridgebiocalcil-ytix-therapeutics-ascendis-pharma-enterabio-shire]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Hypoparathyroidism Market Anticipated to Expand Rapidly During 2024-2034, Says DelveInsight | Bridgebio/Calcil ytix Therapeutics, Ascendis Pharma, EnteraBio, Shire here

News-ID: 3820768 • Views:

More Releases from ABNewswire

Bifacial Solar Market to Grow at a CAGR of 16.30% By 2034 | LONGi Solar, Tigo Energy Inc., Sunpreme Inc
Bifacial Solar Market to Grow at a CAGR of 16.30% By 2034 | LONGi Solar, Tigo En …
Bifacial Solar Market: Exploring growth trends, innovations and regional demand for high-efficiency solar panels capturing energy from both sides. The latest market research report released by Market Research Future suggests, the Bifacial Solar Market [https://www.marketresearchfuture.com/reports/bifacial-solar-market-10149] Size was 10.70 USD Billion in 2024 and it is expected to grow from 12.44 USD Billion in 2025 to 48.43 USD Billion till 2034. The estimated CAGR (growth rate) is around 16.30% during the forecast
Livestock Flooring Market Size, Share, Industry Overview, Growth Drivers, Opportunities, Leading Manufacturers, Recent Developments, and Forecast - 2030
02-18-2025 | Arts & Culture
ABNewswire
Livestock Flooring Market Size, Share, Industry Overview, Growth Drivers, Opport …
Livestock Flooring Market by Product Type (Slat Floors, Interlocking Floors, Grating and Panel Series), Material Type (Concrete, Rubber, Plastic, Steel and Hybrid), Livestock, Farm Type and Region - Global Forecast 2030 The [https://www.marketsandmarkets.com/Market-Reports/livestock-flooring-market-103349855.html] is estimated at USD 1.76 billion in 2025 and is projected to reach USD 2.16 billion by 2030, at a CAGR of 4.2% from 2025 to 2030. Livestock flooring is a specialized solution designed to offer a safe,
Produced Water Treatment Market Projected to Achieve a 5.05% CAGR By 2032 | Siemens AG, Aker Solutions, Schlumberger Limited, Alderley plc
Produced Water Treatment Market Projected to Achieve a 5.05% CAGR By 2032 | Siem …
The Produced Water Treatment Market focuses on technologies for treating water generated during oil and gas production, ensuring environmental compliance and sustainability. According to a comprehensive research report by Market Research Future (MRFR), The Produced Water Treatment Market [https://www.marketresearchfuture.com/reports/produced-water-treatment-market-1596] Information by Well Type, Treatment and Region - Forecast till 2032, The Global Produced Water Treatment Market is estimated to reach a valuation of USD 9.79 Billion at a CAGR of 5.05%
Customized Wholesale Process of Konjac Jelly - ketoslimmo Brand
Customized Wholesale Process of Konjac Jelly - ketoslimmo Brand
The custom wholesale process for konjac jelly involves several key steps to ensure that customers receive a product that satisfies their specific needs and preferences. This process is critical for our future growth and development. Here is the KetoslimMo [https://www.ketoslimmo.com/]custom wholesale process for konjac jelly [https://www.ketoslimmo.com/weight-loss-jelly/]: Image: https://ecdn6-nc.globalso.com/upload/p/1892/image_other/2024-09/customized-wholesale-process-of-konjac-jelly-ketoslimmo-brand.jpg 1. Initial consultation The process begins with an initial consultation between the manufacturer and the customer. During this exchange, the customer's specific requirements, including flavor,

All 5 Releases


More Releases for Hypoparathyroidism

Hypoparathyroidism Treatment Market Size 2022, Upcoming Demand, Regional Outlook …
Global Hypoparathyroidism Treatment Market to reach USD $billion by 2027.Global Hypoparathyroidism Treatment Market is valued at approximately USD $billion in 2020 and is anticipated to grow with a healthy growth rate of more than % over the forecast period 2021-2027. Hypoparathyroidism Treatment is a treatment in which a low level of parathyroid hormone is produced by hypoparathyroidism. Parathyroid hormone maintains and regulates the balance between calcium and phosphorus. Increasing number of
Hypoparathyroidism Treatment Market Size, Share, Trends, Analysis and Forecast 2 …
The Global Hypoparathyroidism Treatment Market is poised to register a CAGR of over 8% during the forecast period 2020 to 2027. Hypoparathyroidism occurs when the parathyroid glands does not produce enough hormone. Hyperparathyroidism can be caused by a number of factors, including injury or removal of the parathyroid glands, DiGeorge syndrome, an autoimmune disease, cancer radiation treatment, and low magnesium levels. The main function of parathyroid hormone is to regulate blood
New Drug Development and Government Support to Root Out Hypoparathyroidism
The global hypoparathyroidism treatment landscape that only gained much significance post the FDA approval of Natpara in 2015, is projected grow at a rather robust CAGR of approximately 8% through 2026. As per a recent in-depth analysis by Future Market Insights (FMI), the valuation of global hypoparathyroidism treatment market is expected to stand at US$ 663.7 Million in 2019. Although the growth rate is expected to showcase similar trends, the
Global Hypoparathyroidism Global Clinical Trials Market Size, Status and Forecas …
This report studies the global Hypoparathyroidism Global Clinical Trials market, analyzes and researches the Hypoparathyroidism Global Clinical Trials development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like Shire Eli Lilly Takeda Aegerion ... Market segment by Regions/Countries, this report covers United States EU Japan China India Southeast Asia Get Free PDF for more Professional and Technical insights @ https://www.qyresearchreports.com/sample/sample.php?rep_id=1040462&type=S Market segment by Type, Hypoparathyroidism Global Clinical Trials can
Hypoparathyroidism-Pipeline Review H2 2017
ReportsWeb.com has announced the addition of the “Hypoparathyroidism-Pipeline Review H2 2017” this report provides an overview of the Non-Hodgkin Lymphoma-Pipeline landscape.  Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Hypoparathyroidism-Pipeline Review, H2 2017, provides an overview of the Hypoparathyroidism (Hormonal Disorders) pipeline landscape. Hypoparathyroidism is decreased function of the parathyroid glands with underproduction of parathyroid hormone. This leads to low levels of calcium in the blood, often causing cramping and twitching of
Research Delivers Insight into the Global Outlook for Hypoparathyroidism Treatme …
Hypoparathyroidism is a conditions when parathyroid glands does not work properly for creation of hormone. Hypoparathyroidism is caused by many reasons as some are like injury or removal of parathyroid glands, DiGeorge syndrome a genetic disorder, autoimmune disease, cancer radiation treatment, and by low magnesium level. The function of parathyroid hormone is to regulate the level of phosphorous and calcium in the blood. The Symptoms of hypoparathyroidism occurs when the